15 results
·
21ms
·
Sources: EU EUDAMED, US FDA
AUTOJECT MINI
FDA 510(k)
FDA Class 2
·General Hospital
Release Laminoplasty Fixation System
FDA 510(k)
FDA Class 2
·Orthopedic
AV Vascular
FDA 510(k)
FDA Class 2
·Radiology
TROJAN PLEASURE PACK LUBRICATED CONDOMS
FDA Adverse Event
Injury
·CHURCH & DWIGHT CO., INC.·Product code HIS·October 29, 2014
D901 LILLIPUT OXYGENATOR
FDA Adverse Event
Malfunction
·SORIN GROUP ITALIA·Product code DTZ·October 13, 2021
CAPSUREFIX
FDA Adverse Event
Injury
·MPRI·Product code NVN·February 9, 2013
COGNIS
FDA Adverse Event
Malfunction
·GUIDANT CRM CLONMEL IRELAND·Product code NIK·January 10, 2011
HOMECHOICE AUTOMATED PD SET WITH CASSETTE
FDA Adverse Event
Malfunction
·BAXTER HEALTHCARE - MOUNTAIN HOME·Product code FKX·July 23, 2014
CUSTOM PERFUSION PACK
FDA Adverse Event
Other
·SORIN GROUP ITALIA·Product code DTZ·October 30, 2012
LILLIPUT 1 START
FDA Adverse Event
Malfunction
·SORIN GROUP ITALIA SRL·Product code DTZ·April 17, 2023
LILLIPUT 1 OXYGENATOR
FDA Adverse Event
Malfunction
·SORIN GROUP ITALY·Product code DTZ·December 27, 2024
LILLIPUT 1 NEW BORN HOLLOW FIBER OXYGENATOR
FDA Adverse Event
Malfunction
·SORIN GROUP ITALIA·Product code DTZ·December 6, 2024
LILLIPUT 1 NEW BORN HOLLOW FIBER OXYGENATOR
FDA Adverse Event
Malfunction
·SORIN GROUP ITALIA SRL·Product code DTZ·January 17, 2022
LILLIPUT 1 NEW BORN HOLLOW FIBER OXYGENATOR
FDA Adverse Event
Malfunction
·SORIN GROUP ITALIA SRL·Product code DTZ·January 25, 2022
Assurity Model Numbers: PM1240, PM2240; Assurity + Model Number: PM2260; Accent Model Numbers: PM1210, PM2210, PM1222, PM2212; Accent MRI Model Numbers: PM1224, PM2218, PM2224 Implantation of a single-chamber pulse generator, dual-chamber pulse generator, or CRT-P is indicated in one or more of the following permanent conditions: Syncope, Presyncope, Fatigue, Disorientation, Or any combination of those symptoms. Implantation of a CRT-P is indicated for: Maintaining synchrony of the left and right ventricles in patients who have undergone an AV nodal ablation for chronic atrial fibrillation and have NYHA Class II or III heart failure. The reduction of the symptoms of moderate to severe heart failure (NYHA Class III or IV) in those patients who remain symptomatic despite stable, optimal medical therapy, and have a left ventricular ejection fraction d35% and a prolonged QRS duration
FDA Enforcement
Class II
·Terminated·St Jude Medical Inc.·October 25, 2017